DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
968
PLUTAVIMAB
2
Antibody
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Unknown
PLUTAVIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VISILIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Lymphoma; Colitis, Ulcerative; Crohn Disease; Graft vs Host Disease; Leukemia, Myeloid, Acute
T-cell surface glycoprotein CD3 epsilon chain inhibitor
VISILIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
H18SKU3289
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HU14.18-IL2
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
HU14.18-IL2
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIIB-023
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Nephritis
Tumor necrosis factor ligand superfamily member 12 inhibitor
BIIB-023
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CLIVATUZUMAB TETRAXETAN
2
Antibody
Investigational
Unknown
Unknown
Pancreatic Neoplasms
Mucin-5AC binding agent
CLIVATUZUMAB TETRAXETAN
×
Maximum Phase:
2
First Approval:
None
UNII:
1D1F7UG35J
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VEPALIMOMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Amine oxidase, copper containing inhibitor
VEPALIMOMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0M19J59UH4
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AME-133V
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Non-Hodgkin
Integrin beta-2 inhibitor
AME-133V
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
L19TNFA
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Fibronectin binding agent
L19TNFA
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-108
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Diabetes Mellitus; Osteoarthritis
Interleukin-1 receptor antagonist
AMG-108
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MIBAVADEMAB
2
Antibody
Investigational
Unknown
Unknown
Lipodystrophy, Congenital Generalized
Unknown
MIBAVADEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EMACTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Non-Hodgkin; Neoplasms
Macrophage colony stimulating factor receptor inhibitor
EMACTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
6FY6EI1X8R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RINUCUMAB
2
Antibody
Investigational
Unknown
Unknown
Macular Degeneration
Platelet-derived growth factor receptor beta inhibitor
RINUCUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
10E3O6YI4W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UPANOVIMAB
2
Antibody
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Unknown
UPANOVIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VX15
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
VX15
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUGEMALIMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Neoplasms; Small Cell Lung Carcinoma; Hodgkin Disease; Lymphoma; Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms
Programmed cell death 1 ligand 1 binding agent
SUGEMALIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
90IQR2I6TR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OLOKIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Osteoarthritis; Crohn Disease; Severe Acute Respiratory Syndrome; Arthritis, Rheumatoid
Interleukin-6 inhibitor
OLOKIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
PAI71R1D2W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
METELIMUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Transforming growth factor beta-1 inhibitor
METELIMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
4AR6718OL0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OMBURTAMAB
2
Antibody
Investigational
Unknown
Unknown
Medulloblastoma; Meningeal Carcinomatosis
Unknown
OMBURTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
XQL6783S5T
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
URTOXAZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Shiga toxin subunit B inhibitor
URTOXAZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
232D35B3NT
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NADECNEMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
NADECNEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CANTUZUMAB MERTANSINE
2
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 binding agent
CANTUZUMAB MERTANSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
7Z7EUX7R6M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PLACULUMAB
2
Antibody
Investigational
Unknown
Unknown
Sciatica; Arthritis, Rheumatoid
TNF-alpha inhibitor
PLACULUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
S80W9W569L
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MTIG7192A
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MTIG7192A
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ERTUMAXOMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms
Receptor protein-tyrosine kinase erbB-2 cross-linking agent
ERTUMAXOMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
L5L45YGP1O
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BLOSOZUMAB
2
Antibody
Investigational
Unknown
Unknown
Osteoporosis, Postmenopausal; Osteoporosis
Sclerostin inhibitor
BLOSOZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
83YOM0NEL5
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REMTOLUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Psoriatic; Arthritis, Rheumatoid
Interleukin 17A inhibitor
REMTOLUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1V8WRH3RVX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UNASNEMAB
2
Antibody
Investigational
Unknown
Unknown
Spinal Cord Injuries
Unknown
UNASNEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ING-1
2
Antibody
Investigational
Unknown
Unknown
Adenocarcinoma
Epithelial cell adhesion molecule other
ING-1
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AD-159
2
Antibody
Investigational
Unknown
Unknown
Unknown
Envelope glycoprotein gp160 inhibitor
AD-159
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUCATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma
Tumor necrosis factor receptor superfamily member 5 antagonist
LUCATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
P0EP9VFC4R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIW-8962
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Mesothelioma; Multiple Myeloma; Small Cell Lung Carcinoma
Disialoganglioside GD2 inhibitor
BIW-8962
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TREGALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Psoriasis
T-cell surface antigen CD4 agonist
TREGALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
43D26MK176
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIBOSTOLIMAB
2
Antibody
Investigational
Unknown
Unknown
Melanoma; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung
T-cell immunoreceptor with Ig and ITIM domains antagonist
VIBOSTOLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
5XO3JF0FEK
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AZ9773
2
Antibody
Investigational
Unknown
Unknown
Unknown
TNF-alpha inhibitor
AZ9773
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
M5A 90Y
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
M5A 90Y
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
11
12
13
14
15
16
17
…
27
28
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA